Halozyme Therapeutics Selected for Inclusion in Prominent Russell 1000® Index
San Diego, CA – [Date of Publication] – Halozyme Therapeutics, Inc. (NASDAQ: HALO), a leading biopharmaceutical company pioneering drug delivery technologies, today announced its addition to the prestigious Russell 1000® Index. This inclusion, effective as of the annual reconstitution of the Russell indexes on June 30, 2025, signifies a significant milestone for Halozyme and reflects its sustained growth and market capitalization.
The Russell 1000® Index is widely recognized as a benchmark for the large-cap segment of the U.S. equity market, comprising the 1000 largest publicly traded companies in the United States, selected based on their market capitalization. Membership in this index typically includes companies with substantial market presence, strong financial performance, and significant influence within their respective industries.
Halozyme’s inclusion is a testament to the company’s robust business model and its impactful contributions to advancing healthcare through its proprietary ENHANZE® drug delivery technology. ENHANZE® is a patented formulation of a proprietary enzyme that temporarily degrades hyaluronan, a naturally occurring substance in the body. This enables the subcutaneous delivery of large-volume medications, potentially transforming the patient experience by offering more convenient, less invasive administration routes compared to traditional intravenous infusions.
“We are honored by Halozyme Therapeutics’ selection for inclusion in the Russell 1000® Index,” said [Name and Title of Halozyme Executive, e.g., Dr. David L. Hall, President and CEO of Halozyme Therapeutics]. “This recognition underscores our commitment to innovation and our dedication to improving patient care through advanced drug delivery solutions. Being part of this influential index provides greater visibility and further validates the significant progress we have made in partnering with leading biopharmaceutical companies to bring life-changing therapies to patients worldwide.”
The ENHANZE® technology is currently leveraged in numerous approved therapies across various therapeutic areas, including oncology, immunology, and rare diseases. Halozyme’s strategic partnerships with major pharmaceutical companies continue to expand the reach and application of its platform, driving innovation and creating value for both patients and shareholders.
Inclusion in the Russell 1000® Index is expected to increase Halozyme’s exposure to institutional investors and a broader range of investment funds that track the index. This could lead to enhanced liquidity for the company’s stock and further solidify its position within the large-cap equity market.
Halozyme Therapeutics remains focused on leveraging its proprietary technology to develop and partner on novel drug delivery solutions that address unmet medical needs and improve the overall treatment landscape. The company’s commitment to scientific excellence and strategic growth positions it for continued success in the years to come.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics is a biopharmaceutical company on a mission to elevate patient experiences and outcomes through innovative drug delivery solutions. Our proprietary ENHANZE® drug delivery technology, a patented formulation of a proprietary enzyme, is designed to facilitate the subcutaneous delivery of large-volume therapeutic molecules, potentially transforming how medications are administered. Halozyme partners with leading pharmaceutical and biotechnology companies to advance a broad range of products across multiple therapeutic areas. For more information, please visit [Halozyme’s website address].
Forward-Looking Statements
This press release contains forward-looking statements regarding Halozyme Therapeutics, Inc. and its business, including statements about the benefits and impact of inclusion in the Russell 1000® Index and the company’s future prospects. These forward-looking statements are based on current expectations and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks and uncertainties include, but are not limited to, the ability to develop and commercialize new drug delivery solutions, the success of our partnerships, regulatory approvals, competition, and other factors discussed in Halozyme’s filings with the Securities and Exchange Commission. Halozyme undertakes no obligation to update any forward-looking statements.
Contact:
[Name of Investor Relations Contact] [Title] [Email Address] [Phone Number]
Halozyme Therapeutics Added to Russell 1000® Index
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Policy Public Interest published ‘Halozyme Therapeutics Added to Russell 1000® Index’ at 2025-06-30 20:05. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.